PD150606
Based on 14 publication(s) in Google Scholar
PD 150606 is a selective, cell-permeable non-peptide calpain inhibitor with Ki values of 0.21 μM and 0.37 μM for μ- and m-calpains respectively, which is neuroprotective.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.61%
- No. CAS: 179528-45-1
- Fòrmula: C9H7IO2S
- Peso molecular:306.12
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-diabetic Compound Library
HY-L040
-
Ubiquitination Compound Library
HY-L050
-
Neuroprotective Compound Library
HY-L070
-
Anti-Blood Cancer Compound Library
HY-L079
-
Targeted Diversity Library
HY-L099
-
Protease Inhibitor Library
HY-L147
-
Cysteine Targeted Covalent Library
HY-L153
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) PD150606
More- Nature. 2025 May;641(8061):202-210. [Abstract]
- Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
- J Hazard Mater. 2022 Feb 15;424(Pt A):127318. [Abstract]
- Pharmacol Res. 2022 May 19;181:106262. [Abstract]
- Apoptosis. 2025 Sep 30. [Abstract]
- J Genet Genomics. 2024 Oct;51(10):1020-1029. [Abstract]
- Cell Rep. 2023 Dec 2;42(12):113522. [Abstract]
- EMBO Rep. 2023 Apr 5;24(4):e55069. [Abstract]
- J Cell Physiol. 2025 Apr;240(4):e70036. [Abstract]
- Exp Cell Res. 2020 Jun 1;391(1):111886. [Abstract]
- Toxicol Appl Pharmacol. 2023 Jul 15:471:116568. [Abstract]
- J Peripher Nerv Syst. 2024 Dec;29(4):555-566. [Abstract]
- Int Heart J. 2021 Jul 30;62(4):900-909. [Abstract]
- Research Square Preprint. 2024 Jan 2.
Customer Validation & Images
-
WB
-
IF
-
WB
-
Cell Imaging/Staining
Actividad biológica
Ki: 0.21 μM (μ-calpains), 0.37 μM (m-calpains)[1]
PD150606 interacts with both calcium-binding domains (μ- and m-calpains) of Calpain[1].
PD150606 attenuates hypoxic/hypoglycemic injury to cerebrocortical neurons in culture and excitotoxic injury to Purkinje cells in cerebellar slices[1].
PD 150606 (25 μM; 0-12 hours) reduces Cycloheximide (10 mg/ml) -triggered apoptosis of neutrophils[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 179528-45-1
-
Appearance Solid
-
Peso molecular 306.12
-
Fòrmula C9H7IO2S
-
Color Off-white to yellow
-
SMILES
O=C(O)/C(S)=C/C1=CC=C(I)C=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 May;641(8061):202-210. PMID: 40140567 -
Mol Cancer
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. [Abstract]2024 Sep 30;23(1):215. PMID: 39350121
PD150606 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
Western blot analysis of RXRα expression after 24 h of treatment with PD150606 (200 nM, m-calpain inhibitor) or ZFY-CHO (10 µM, CTSL inhibitor).
-
J Hazard Mater
Chlorpyrifos triggers epithelioma papulosum cyprini cell pyroptosis via miR-124-3p/CAPN1 axis. [Abstract]2022 Feb 15;424(Pt A):127318. PMID: 34879549 -
Pharmacol Res
TRPC1 contributes to endotoxemia-induced myocardial dysfunction via mediating myocardial apoptosis and autophagy. [Abstract]2022 May 19;181:106262. PMID: 35598715 -
Apoptosis
Regulated cell death environments drive fibroinflammatory reprogramming in surviving adipose-derived stem cells. [Abstract]2025 Sep 30. PMID: 41028407 -
J Genet Genomics
2024 Oct;51(10):1020-1029. PMID: 38663479 -
Cell Rep
Cell-cell and cell-matrix adhesion regulated by Piezo1 is critical for stiffness-dependent DRG neuron aggregation. [Abstract]2023 Dec 2;42(12):113522. PMID: 38048221
PD150606 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Dec 2;42(12):113522. [Abstract]
Representative immunofluorescence images of DRG neurons seeded on laminin-coated glass slides and treated with culture medium (control), 10 μM PD150606 or 30 μM Yoda1 for 24 hours.
PD150606 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Dec 2;42(12):113522. [Abstract]
Western blots of integrin-β1, SN25, and GAPDH in DRG neurons seeded on glass slides and treated with 10 μM PD150606 for 30 min at DIV1.
PD150606 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Dec 2;42(12):113522. [Abstract]
Representative images were cultured on substrates at 5.0 and 20 kPa and incubated for 24 hours with medium (control) or 10 μM PD150606.
-
EMBO Rep
The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential. [Abstract]2023 Apr 5;24(4):e55069. PMID: 36744297 -
J Cell Physiol
2025 Apr;240(4):e70036. PMID: 40237554 -
Exp Cell Res
Inhibition of the ERK1/2-ubiquitous calpains pathway attenuates experimental pulmonary fibrosis in vivo and in vitro. [Abstract]2020 Jun 1;391(1):111886. PMID: 32017927 -
Toxicol Appl Pharmacol
Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase. [Abstract]2023 Jul 15:471:116568. PMID: 37245555 -
J Peripher Nerv Syst
The NCX1 calcium exchanger is implicated in delayed axotomy after peripheral nerve stretch injury. [Abstract]2024 Dec;29(4):555-566. PMID: 39402795 -
Int Heart J
Inhibition of Calpain Alleviates Apoptosis in Coxsackievirus B3-induced Acute Virus Myocarditis Through Suppressing Endoplasmic Reticulum Stress. [Abstract]2021 Jul 30;62(4):900-909. PMID: 34234076 -
Solvente y solubilidad
DMSO : ≥ 28 mg/mL (91.47 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.17 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.17 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (641 KB)
- English - EN (641 KB)
- Français - FR (641 KB)
- Deutsch - DE (641 KB)
- Norwegian - NO (641 KB)
- Español - ES (641 KB)
- Swedish - SV (641 KB)
- Italian - IT (641 KB)
- Korean - KR (641 KB)
- Portuguese - PT (641 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. 1. Wang KK et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6687-92. [Content Brief]
[2]. 2. Squier MK , et al. Calpain and calpastatin regulate neutrophil apoptosis. J Cell Physiol. 1999 Mar;178(3):311-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2667 mL | 16.3335 mL | 32.6669 mL | 81.6673 mL |
| 5 mM | 0.6533 mL | 3.2667 mL | 6.5334 mL | 16.3335 mL | |
| 10 mM | 0.3267 mL | 1.6333 mL | 3.2667 mL | 8.1667 mL | |
| 15 mM | 0.2178 mL | 1.0889 mL | 2.1778 mL | 5.4445 mL | |
| 20 mM | 0.1633 mL | 0.8167 mL | 1.6333 mL | 4.0834 mL | |
| 25 mM | 0.1307 mL | 0.6533 mL | 1.3067 mL | 3.2667 mL | |
| 30 mM | 0.1089 mL | 0.5444 mL | 1.0889 mL | 2.7222 mL | |
| 40 mM | 0.0817 mL | 0.4083 mL | 0.8167 mL | 2.0417 mL | |
| 50 mM | 0.0653 mL | 0.3267 mL | 0.6533 mL | 1.6333 mL | |
| 60 mM | 0.0544 mL | 0.2722 mL | 0.5444 mL | 1.3611 mL | |
| 80 mM | 0.0408 mL | 0.2042 mL | 0.4083 mL | 1.0208 mL |
PD150606 Related Classifications
HY-100529 Related Classifications
Powered by Bioz